Medicine Description versapenia 50mg
Versapenia Tablets are indicated for the treatment of thrombocytopenia (low platelet count). They belong to the
thrombopoietin receptor agonist class and contain the active ingredient eltrombopag olamine. The medication stimulates
the bone marrow to increase platelet production, helping reduce the risk of bleeding.
It is used in the management of chronic immune thrombocytopenia (ITP) in both adults and children. It also supports
the treatment of thrombocytopenia associated with chronic hepatitis C and severe aplastic anemia, providing an
advanced therapeutic option under specialist medical supervision.
Versapenia Ingredients
Eltrombopag.
Versapenia Strengths
Film-coated tablets, 50 mg, pack containing 30 tablets.
Uses of Versapenia
Treatment of chronic immune thrombocytopenia (ITP).
Increasing platelet counts in patients with chronic hepatitis C to enable the initiation or continuation of
interferon-based therapy.
Treatment of severe aplastic anemia in patients who have not responded adequately to first-line therapy.
Reducing the risk of serious bleeding associated with low platelet counts.
Versapenia Dosage
The usual starting dose for adults is 50 mg once daily. The physician may adjust the dose based on the patient's
response and platelet count monitoring.
Take the tablet on an empty stomach, either one hour before or two hours after meals. Follow your physician's
prescribed dosage schedule carefully.
Side Effects of Versapenia
Nausea, vomiting, or mild diarrhea.
Headache, fatigue, or muscle and joint pain.
Mild elevation of liver enzymes in some patients.
Contraindications of Versapenia
Do not use Versapenia if you are allergic to eltrombopag olamine or any of the product's ingredients.
Use with caution and under close medical supervision in patients with severe liver impairment or those at increased
risk of venous or arterial thromboembolic events.
Versapenia Alternatives
Revolade.
Use During Pregnancy and Breastfeeding
The use of Versapenia during pregnancy is generally not recommended unless the expected benefit to the mother clearly
outweighs the potential risk to the fetus, as determined by the treating physician.
Breastfeeding should be discontinued during treatment because there are insufficient data regarding the excretion of
eltrombopag into human breast milk.
Women of childbearing potential should consult their physician before starting treatment and use effective
contraception throughout therapy as recommended.
Storage Conditions
Store at room temperature below 30°C.
Keep in a dry place away from moisture and direct sunlight.
Store the tablets in their original, tightly closed package.
Keep out of the reach of children.